Currently there are few therapeutic options for the treatment of lid retraction secondary to thyroid orbitopathy (TO) during the active stages of the disease. BoTox injection is capable of creating a ptosis, that in the setting of TO can return the upper lid to a more physiologic position, thus improving cosmesis, corneal lubrication and potentially quiescent stage lid position. This investigation aims to examine the properties of this relationship.

Active stage thyroid orbitopathy, as determined by symptom onset of under 6 months.

Upper eyelid retraction of 1mm or greater.

Complaining of either significant ocular symptoms (despite appropriate use of ocular lubricants), or bothered by the cosmetic deformity associated with the eyelid retraction.

Exclusion Criteria:

Less than 18 years of age

Age over 65 years

Pregnant or nursing

Known peripheral neuropathy or neuromuscular junction disorder

Demonstrated allergy to BoTox

Current infection over the injection site

Are currently taking any of the following medications: aminoglycosides, penicillamine, quinine, and calcium channel blockers.

Previous or concurrent prednisone therapy

Undergone previous upper eyelid surgery

Severe vision threatening TO

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01272414